Drug Pipeline
5 drugs associated with Autosomal recessive osteopetrosis
| Drug | Phase | Sponsor | |
|---|---|---|---|
Melatonin2%gel | Approved | Al-Azhar University | ↗ |
RP-L401 | Phase 1 | Rocket Pharmaceuticals Inc. | ↗ |
Actimmune Registry Interferon gamma receptor agonist | unknown | InterMune | ↗ |
Bisoprolol Though the mechanism of action of bisoprolol has not been fully elucidated in hypertension, it is thought that therapeutic effects are achieved through the antagonism of β-1adrenoceptors to result in lower cardiac output. Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. When β1-receptors (located mainly in the heart) are activated by adrenergic neurotransmitters such as epinephrine, both the blood pressure and heart rate increase, leading to greater cardiovascular work, inc | unknown | National Research Center for Preventive Medicine | ↗ |
Moxonidine Stimulation of central alpha 2-adrenergic receptors is associated with sympathoadrenal suppression and subsequent reduction of blood pressure. As this class was further explored it was discovered that sympathoadrenal activity can also be suppressed by a second pathway with a newly discovered drug target specific to imidazolines. Specifically, moxonidine binds the imidazoline receptor subtype 1 (I1) and to a lesser extent αlpha-2-adrenoreceptors in the RSV causing a reduction of sympathetic activ | unknown | National Research Center for Preventive Medicine | ↗ |